The PROCLIPI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas - 29/05/22
ABSTRACT |
PROCLIPI is the PROgnostic Cutaneous Lymphoma International Prognostic Index Study with the main aim to produce a prognostic index in mycosis fungoides (MF) and Sezary syndrome (SS). The study prospectively collects clinical, haematological, pathological, imaging, treatment with responses, quality of life and survival data using careful predefined datasets. Patients are subject to a central review to confirm diagnosis. PROCLIPI opened in 2015 and recruitment has been strong with to date 1916 patients recruited from 52 Centres from 19 countries across 6 continents.
Le texte complet de cet article est disponible en PDF.Plan
Vol 51 - N° 1
Article 104123- mars 2022 Retour au numéro
Article précédent
- New developments in skin-directed treatments of cutaneous T-cell lymphoma
- Iris Amitay-Laish, Emmilia Hodak
- Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification
- Rein Willemze
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?